Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Clinical Practice Guidelines – Thyroid cancer

with different risks of malignancy [11]. Most malignant thyroid tumours can be identi?ed cytologically. Notable exceptions are FTCs and the newly de?ned ‘non-invasive follicular thyroid neoplasm with papillary-like nuclear features’ (NIFTP), which are usually classi?ed as indeterminate in the vari- ous thyroid cytology reporting schemes [12]. FNA-based diagno- sis of poorly differentiated carcinoma is also challenging unless there is obviously increased mitotic activity and/or necrosis. FNA diagnosis can (...) Including papillary, follicular, Hu ¨rthle cell and poorly differentiated carcinomas. ATC, anaplastic thyroid cancer; pN, pathological node; pT, pathological tumour; TNM, tumour, node, metastasis; UICC, Union for International Cancer Control. Adapted from [23] with permission from John Wiley & Sons, Inc. Annals of Oncology Special article Volume 30 | Issue 12 | 2019 doi:10.1093/annonc/mdz400 | 1859Table 3. Risk strati?cation system for the prediction of persistent or recurrent disease in DTC patients

2020 European Society for Medical Oncology

2. Cancer Patient Management During COVID-19 Pandemic

that older people are more vulnerable, with underlying health conditions such as chronic respiratory, cardio-vascular or chronic kidney disease, diabetes, active cancer and more generally severe chronic diseases. Therefore, during the COVID-19 pandemic, the Benefit/Risk ratio of cancer treatment may need to be reconsidered in certain patients. Two groups of patients have been identified: “patients off therapy” (A) who have completed a treatment or have disease under control (off therapy); and patients (...) . Clinical staff responsible for the checkpoint area should be trained and wear PPE. Individuals who meet criteria for highly communicable diseases requiring isolation, such as novel COVID-19 or other emerging infections, must be placed in a private exam room as soon as possible, as per the infectious control guidance found on the WHO and CDC websites. They should be tested and transferred to COVID-19 dedicated areas. In cancer patients, categories at risk include: Patients receiving chemotherapy, or who

2020 European Society for Medical Oncology

3. eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations

cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001 (...) durvalumab, 1 to 42 days after the end of chemoradiotherapy has demonstrated a survival benefit in unresectable stage III NSCLC and is recommended in patients whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy (as per the EMA approved indication) [I, A; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 4] in the intention to treat population across all PD-L1 categories]. ESMO

2020 European Society for Medical Oncology

4. Trastuzumab (Herzuma) - Breast Cancer and Gastric Cancer

Trastuzumab (Herzuma) - Breast Cancer and Gastric Cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2020 Health Canada - Drug and Health Product Register

5. Prevalence of dysphagia and economic burden of aspiration pneumonia in patients with stroke or head and neck cancer

Prevalence of dysphagia and economic burden of aspiration pneumonia in patients with stroke or head and neck cancer application/octet-stream

2020 Institute of Health Economics

6. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 212 2 Information about lorlatinib Information about lorlatinib Marketing authorisation indication Marketing authorisation indication 2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non- small cell lung cancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK (...) that there was a significant unmet need for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), even though 4 ALK tyrosine kinase inhibitor (TKI) treatments are available. The committee noted that neither crizotinib nor ceritinib are preferred for untreated disease since the availability of alectinib. Brigatinib has been approved for previously treated disease only after crizotinib. If alectinib's treatment effect wanes the only current option is chemotherapy. ALK TKI treatments

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

7. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Full Text available with Trip Pro

toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group . Wang Z , Yang B , Li Q , et al . Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China . Teachey DT , Lacey SF , Shaw PA , et al . Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia . pmid: http://www.ncbi.nlm.nih.gov (...) Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 | Journal for ImmunoTherapy of Cancer Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword

2020 Society for Immunotherapy of Cancer

8. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response Full Text available with Trip Pro

, interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα). This pro-inflammatory cytokine profile has been with poor prognosis and severe lung pathology characterized by interstitial mononuclear inflammatory infiltrates, diffuse alveolar damage, hyaline membrane formation and pulmonary edema. As the oncology community rallies behind our colleagues in intensive care, internal medicine, emergency medicine and infectious disease, the immunotherapy field is poised to offer insights into the application (...) to hydroxyurea and steroid-refractory graft versus host disease in adult and pediatric patients aged 12 years and older. Tofacitinib (Xeljanz ® , Jakvinus, Pfizer) is an oral JAK inhibitor with selectivity for JAK1 and JAK3 indicated for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. The occurrence of serious infections and lymphoid-associated malignancies have led to a current black box warning imposed by the FDA. Baricitinib (Olumiant ® , Eli-Lilly) is an oral JAK

2020 Society for Immunotherapy of Cancer

9. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement - Gynecologic Oncology Email/Username: Password: Remember me Search Terms Search within Search Volume 157, Issue 2, Pages 303–306 To read this article in full, please review your options (...) for gaining access at the bottom of the page. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement This practice statement has been endorsed by The North American Menopause Society x A.K. Sinno Affiliations University of Miami Miller School of Medicine, Miami, FL, USA Correspondence Corresponding author at: University of Miami Miller School of Medicine, 1121 NW 14 th Street

2020 Society of Gynecologic Oncology

10. Use of cannabinoids in cancer patients

Use of cannabinoids in cancer patients Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement - Gynecologic Oncology Email/Username: Password: Remember me Search Terms Search within Search Volume 157, Issue 2, Pages 307–311 To read this article in full, please review your options for gaining access at the bottom of the page. Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement x B (...) . Whitcomb Affiliations University of Connecticut Health, The Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA Correspondence Corresponding author at: University of Connecticut Health, The Carole and Ray Neag Comprehensive Cancer Center, 263 Farmington Avenue, Farmington, CT 06030, USA. a , , x B. Whitcomb Affiliations University of Connecticut Health, The Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA Correspondence Corresponding author at: University

2020 Society of Gynecologic Oncology

11. An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

be offered as an alternative to conventional fractionation. The task force strongly encourages that these patients be treated as part of a clinical trial or multi-institutional registry. Comment: There is additional RCT evidence to support the recommendation of KQ3B that may increase the quality of evidence for the use of ultrahypofractionation in intermediate-risk disease from low to at least moderate [2]. ENDORSED with comment KQ3C: In men with high-risk prostate cancer receiving EBRT, the task force (...) with the recommendations for information purposes. Guideline Endorsement 3-22 Section 2: Endorsement Methods Overview – April 28, 2020 Page 5 Selection of Guidelines The Radiation Treatment Program, Disease Pathway Management, Ontario GU Cancers Advisory Committee, GU disease site group (DSG) chairs reviewed the ASTRO, ASCO, and AUA evidence-based guideline on hypofractionated radiation therapy for localized prostate cancer and accepted it as potentially useful and relevant to guide practice in Ontario. Assessment

2020 Cancer Care Ontario

12. Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer

and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials April 2019, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to May 16, 2019 Search Strategy: # Searches 1 exp lung neoplasms/ or exp lung cancer/ 2 (((lung or thorax or thoracic or pulmonary) adj3 (cancer$ or neoplasm$ or carcinom$ or malignan$ or tumo?r$ or adenocarcinoma$)) or NSCLC).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, ui, sy, sh, tx, ct] 3 1 or 2 4 exp (...) , P.M. Ellis, R. Goffin, W. Hanna, D. Maziak, A. Swaminath, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: April 27, 2020 This document describes the OH (CCO)-Lung Cancer Disease Site Group endorsement of the recommendations for the treatment of patients with clinical stage III N2 non-small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available at www.nice.org.uk/guidance/ng122. The recommendations were also endorsed

2020 Cancer Care Ontario

13. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Lancet Oncol Actions . 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology, Odense University Hospital, Odense, Denmark; Department

2020 EvidenceUpdates

14. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212) Full Text available with Trip Pro

RFS among patients with clinical stage III disease who underwent ME with LLND compared with ME alone (HR 1·49, 1·02 to 2·17). Conclusion: Long-term follow-up data did not support the non-inferiority of ME alone compared with ME and LLND. ME with LLND is recommended for patients with clinical stage III disease, whereas LLND could be omitted in those with clinical stage II tumours. Antecedentes: El JCOG0212 (ClinicalTrials.gov: ) fue un ensayo fase III de no inferioridad en pacientes con cáncer de (...) Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212) Long-term Follow-Up of the Randomized Trial of Mesorectal Excision With or Without Lateral Lymph Node Dissection in Rectal Cancer (JCOG0212) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable

2020 EvidenceUpdates

15. ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic Full Text available with Trip Pro

ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic | Blood | American Society of Hematology ') Advertisement search input Search input auto suggest search filter Article Navigation April 10, 2020 ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic Joachim Yahalom Memorial Sloan (...) -Kettering Cancer Center, New York, New York, United States * Corresponding Author; email: Search for other works by this author on: , Bouthaina S. Dabaja MD Anderson Cancer Center, Houston, Texas, United States Search for other works by this author on: , Umberto Ricardi University of Turin, Turin, Italy Search for other works by this author on: , Andrea Ng Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, United States Search for other works by this author on: , N. George

2020 Covid-19 Ad hoc guidelines

16. ACS Guidelines for Triage and Management of Elective Cancer Surgery Cases During the Acute and Recovery Phases of Coronavirus Disease 2019 (COVID-19) Pandemic

progressing on neoadjuvant therapy • Priority B3: o Clinical stage T2 or N1 ER+HER2- tumors †‡ o Discordant biopsies likely to be malignant, i.e., ER- ductal carcinoma in situ (DCIS) that presents as a palpable mass o Malignant or suspected local recurrence *In some cases, institutions may decide to proceed with surgery rather than subject a patient to an immunocompromised state with neoadjuvant chemotherapy; these decisions will depend on institutional resources. † Encourage use of breast-conserving (...) neoadjuvant chemotherapy for inflammatory breast cancer o TNBC or HER2+ patients who are not undergoing upfront neoadjuvant therapy • Priority B2: o Patients finishing neoadjuvant therapy where there is a window of time that surgery should be performed o Patients progressing on neoadjuvant therapy • Priority B3: o Clinical stage T2 or N1 ER+HER2- tumors o Discordant biopsies likely to be malignant, i.e., ER- DCIS that presents as a palpable mass o Malignant or suspected local recurrence Cases that could

2020 American College of Surgeons

17. Evidence Report for Investigating symptoms of lung cancer: a guide for all health professionals

, which can hinder early diagnosis and treatment. 4, 5 Lung cancer presentations can also be complex, due to co-morbidities or plausible alternative diagnoses. 6 Lung cancer symptoms can present in a similar manner to other conditions such as chronic obstructive pulmonary disease (COPD), chronic heart failure and coronary heart disease. 7 Therefore, it is important to increase awareness of lung cancer symptoms and risk factors, and to provide all health professionals with the most recent evidence (...) with symptoms or signs consistent with lung cancer. The Guide does not provide advice on the following: • adults with mesothelioma • adults with lung metastases arising from primary cancer originating outside the lung • children (younger than 18 years) with lung cancer • adults with rare lung tumours • adults with benign lung tumours, and • adults being screened for lung cancer. For more information on the potential role of screening for asymptomatic patients, visit Cancer Australia’s lung cancer screening

2020 Cancer Australia

18. Investigating symptoms of lung cancer: a guide for all health professionals

The association of lung cancer with smoking can lead to lung cancer patients feeling stigmatised, contributing to delays in help-seeking for symptoms 4,5 and psychological distress. 6 Risk factors for lung cancer Lifestyle factors - current or former tobacco smoking Environmental or occupational factors - passive smoking - occupational exposures e.g. radon, asbestos, diesel exhaust, silica - air pollution Personal factors - increasing age - family history of lung cancer - chronic lung disease e.g. chronic (...) obstructive pulmonary disease (COPD), pulmonary fibrosis - personal history of cancer e.g. lung cancer, head and neck cancer, bladder cancer Symptoms and signs of lung cancer Symptoms can present in a similar manner to other conditions such as COPD, chronic heart failure and coronary heart disease. 7 Please refer to the flow chart overleaf for symptoms and signs of lung cancer, recommended investigations and referrals, and timeframes for referral. 80 90 100 70 60 50 40 30 20 10 Stage at diagnosis and 5

2020 Cancer Australia

19. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck

. This guideline aims to define the best evidence for the diagnosis and management of SCCUP. Management decisions for SCCUP are best decided in the context of a multidisciplinary tumor board and with careful consideration of HPV status, disease burden and distribution in the neck, a patient’s overall health and well-being, potential treatment-related toxicity, and rehabilitation potential for functional recovery. THE BOTTOM LINE Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head (...) % of cases. The difficulties in finding the primary tumors may be explained by their small size as well as the difficult access to anatomic locations that can be missed by physical examinations and/or imaging studies. The presence of a neck mass in adults for over two weeks and without evidence of infection is highly suspicious of malignancy. Diagnostic delays may result in progression of disease with increased morbidity, loss of function, and increased mortality. , Concerning associated symptoms

2020 American Society of Clinical Oncology Guidelines

20. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

or Thrombocytosis 17 Primary Myelofibrosis 18 Genetic Testing for Hematologic Malignancy 18 Minimal Residual Disease (MRD) Genetic Testing 18 Solid Tumor Testing 19 NTRK Fusion Testing 19 PIK3CA Testing 20 Breast Cancer 20 Lung Cancer 22 Cell-Free Tumor Testing 23 Cancer of Unknown Primary/Occult Neoplasm 23 Pancreatic Cancer 24 Prostate Cancer 25 Thyroid Cancer 26 Cancer Screening 26 Indeterminate Thyroid Nodules 26 Colorectal Cancer Screening 28 Professional Society Guidelines 29 PROPRIETARY Guidelines (...) . All Rights Reserved. 6 ? Hepatobiliary cancer ? Kidney cancer ? Malignant pleural mesothelioma ? Merkle cell carcinoma ? Multiple myeloma ? Neuroendocrine and adrenal tumors - including gastrointestinal and lung ? Non-epithelial ovarian cancers or borderline epithelial tumors (low malignant potential) ? Occult primary ? Pancreatic cancer ? Prostate cancer - post-diagnosis gene expression classifiers ? Skin cancer - basal and squamous cell ? Small cell lung cancer ? T-cell lymphoma: cutaneous

2020 AIM Specialty Health